BOSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that it will report fourth quarter 2025 financial results on March 5, 2026, before the open of the U.S. financial markets. The company does not intend to hold a conference call. Additionally, Tango Therapeutics management is scheduled to participate in three upcoming investor conferences: TD Cowen 46th Annual Health Care Conference, Boston Corporate presentation on Wednesday, March 4 at 1:10-1:40 PM ETWebcast ...

Summary of Tango Therapeutics Conference Call Company Overview - **Company**: Tango Therapeutics (NasdaqGM:TNGX) - **New CEO**: Malte Peters, who has been a board member since 2018 and emphasizes continuity in strategy following the transition from former CEO Barbara. Key Priorities and Strategic Focus - **Regulatory Approval**: The primary focus is to achieve regulatory approval for vopimetostat, either as a monotherapy or in combination with RAS inhibitors [4][5]. - **Clinical Development**: Transitioning Tango into a late-phase drug development company is a key priority, with a pivotal trial protocol developed for second-line pancreatic cancer [4][6]. Clinical Trials and Data - **Pivotal Trial for Pancreatic Cancer**: A pivotal trial protocol for second-line pancreatic cancer has been developed, with positive feedback from the FDA regarding trial design and statistical analysis [6][11]. - **Combination Trials**: A combination trial of vopimetostat with RevMed's RAS inhibitors (daraxonrasib and zoldonrasib) has been initiated, showing early signs of clinical activity [6][16]. - **Monotherapy Study**: A 300-patient study is planned, focusing on progression-free survival (PFS) and overall survival [9][12]. - **Promising Data**: Previous monotherapy data indicated a 25% overall response rate (ORR) and approximately 7 months PFS in pancreatic cancer [12]. Market and Competitive Landscape - **Global Trial Design**: The study will be conducted globally, including the USA, Europe, and Asia Pacific, to enhance patient recruitment [11]. - **Chemo-Free Regimen**: There is significant interest in developing a chemotherapy-free regimen for pancreatic cancer, which could greatly benefit patients [37][41]. - **Comparison with Competitors**: Tango is pursuing a different strategy than competitors like BMS, focusing on non-chemotherapy combinations due to scientific and financial considerations [40][41]. Future Directions and Opportunities - **Expansion into Other Tumor Types**: The company is exploring opportunities in other tumor types with MTAP deletions, showing promising signals in head and neck cancer [45][46]. - **TNG456 Development**: The TNG456 clinical trial is in dose escalation, with plans to explore its potential in glioblastoma and non-small cell lung cancer [42][43]. - **Combination with Abemaciclib**: There are plans to pursue a combination with abemaciclib based on preclinical data suggesting potential benefits [49]. Upcoming Updates - **Data Releases**: Updates on pancreatic cancer monotherapy data, combination data with Revolution Medicines, and TNG456 dose escalation data are expected later this year [51][56]. Conclusion - **Exciting Year Ahead**: The company anticipates a year filled with significant developments and data releases, positioning itself for potential breakthroughs in cancer treatment [56].

Core Insights - Tango Therapeutics, Inc. is participating in the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026, at 2:00 PM EST, with CEO Malte Peters scheduled for a fireside chat [1] - The event will be accessible via a live webcast on the company's website, with a replay available for 90 days post-presentation [2] - Tango Therapeutics is focused on discovering novel drug targets and developing precision medicine for cancer treatment, utilizing the genetic principle of synthetic lethality [3]

Group 1 - The article discusses the importance of enabling Javascript and cookies in browsers to prevent access issues [1] - It highlights that users with ad-blockers may face restrictions when trying to access content [1]

Company Overview - Tango Therapeutics has appointed Malte Peters as the new CEO, succeeding Barbara Weber, who served as CEO until last Thursday [2][3] - Barbara Weber will continue to serve as Executive Chairman and has been instrumental in the company's development since its inception [2][3] Leadership Transition - Malte Peters has a strong background in the pharmaceutical industry, having previously served as Chief R&D Officer at MorphoSys, which is relevant to Tango's future development needs [3] - The leadership change is part of a strategic move as the company prepares to advance its key drug, vopimetostat, which is considered crucial for the company's future [4]

Summary of Tango Therapeutics FY Conference Call Company Overview - **Company**: Tango Therapeutics (NasdaqGM:TNGX) - **Date of Conference**: January 14, 2026 - **New CEO**: Malte Peters, who succeeded Barbara Weber as CEO Key Points and Arguments Leadership Transition - Barbara Weber, the founding CEO, transitioned leadership to Malte Peters, emphasizing the need for a focus on late-phase drug development and regulatory discussions [2][3][29] - Peters has a background in R&D and has been involved with Tango since 2018, ensuring a smooth transition [2][30] Pipeline and Drug Development - Tango is moving from clinical validation to late-phase drug development, focusing on drugs targeting MTAP deletions in cancer [4][6] - **Pipeline Highlights**: - **TNG462**: In dose expansion studies, targeting approximately 60,000 patients annually in the U.S. with MTAP deletions [5][9] - **TNG456**: A blood-brain barrier penetrant molecule entering phase one clinical trials [5][9] - **TNG961**: An HBS1L degrader ready for clinical trials, targeting FOCAT deletion in MTAP-deleted cancers [19] Clinical Milestones for 2026 - Launch a pivotal trial in second-line pancreatic cancer [6][20] - Complete TNG462 RAS inhibitor combination studies [6][20] - Expand knowledge base in lung cancer and other indications [6][20] - Evaluate TNG456 efficacy in glioblastoma [6][20] Competitive Advantages - Received FDA support for pivotal trial protocol and statistical analysis plan [12][8] - Best-in-class potential for TNG462 based on selectivity, potency, and safety profile [8][9] - First company to combine a PRMT5 inhibitor with RAS inhibitors in clinical trials [9] Clinical Data Insights - TNG462 shows a 27% response rate and a median progression-free survival (PFS) of 6.4 months across multiple tumor histologies [10] - Comparison with standard care indicates a potential doubling of median PFS for patients with MTAP deletions [11][12] - A 49% response rate observed in a histology-selective cohort with a median PFS of 9.1 months [17] Strategic Focus - Emphasis on addressing high unmet medical needs in difficult-to-treat cancers [6] - Potential for a chemo-free treatment regimen for pancreatic cancer patients [15] - Commitment to robust data before public disclosure, independent of medical meetings [27] Other Important Content - Discussion on the mechanism of PRMT5 inhibitors and their reliance on MTAP deletion for therapeutic efficacy [22] - Peters' priorities include rapid advancement into late-phase drug development and regulatory readiness [23] - Barbara Weber highlighted the successful transition from a genomic target discovery platform to readiness for pivotal studies [28] This summary encapsulates the critical aspects of Tango Therapeutics' conference call, focusing on leadership changes, pipeline developments, clinical milestones, competitive advantages, and strategic focus.

Pipeline and Clinical Development - Vopimetostat, a PRMT5 inhibitor, is in dose expansion for MTAP-del cancers and dose escalation for RAS-mut pancreatic and lung cancer, including combinations with RAS inhibitors[13] - TNG456, a brain-penetrant PRMT5 inhibitor, is in dose escalation for MTAP-del glioblastoma[13] - TNG961, an HBS1L degrader, has Phase 1 enabled for MTAP/FOCAD-del solid tumors[13] - A pivotal study for vopimetostat monotherapy in 2L MTAP-del pancreatic cancer is planned to start in 2026[23, 37] - Early data from the vopimetostat + RAS(ON) inhibitor clinical study is encouraging, with 30 patients dosed and both combinations well-tolerated[45, 48] Vopimetostat Clinical Data - Vopimetostat monotherapy demonstrated an Overall Response Rate (ORR) of 27% across 16 different histologies and a Disease Control Rate (DCR) of 78%[30] - In 2L pancreatic cancer, vopimetostat showed a median Progression-Free Survival (mPFS) of 7.2 months, more than twice historical Standard of Care (SOC) trials[32, 35] - In a histology-selective cohort, vopimetostat achieved an ORR of 49%, a DCR of 89%, and an mPFS of 9.1 months[50, 53] Financial Status - The company reported a cash balance of $343 million as of December 31, 2025, providing a cash runway into 2028[19, 81] Glioblastoma Focus - TNG456 is being developed for MTAP-del glioblastoma, which represents 45% of GBM cases, or approximately 7,000 patients per year in the US[23]

Compensation and Benefits - The Executive's initial base salary is set at $720,000 per year, subject to periodic review and potential increase by the Board[6]. - The Executive is eligible for an initial target annual incentive compensation of 60% of the Base Salary, which will be determined based on performance objectives[7]. - The Executive will receive a monthly housing allowance of $15,000 gross for the first two years of the Term, once the required visa is obtained[9]. - The Executive will be granted new hire equity awards consisting of 1,650,000 stock options and 350,000 restricted stock units, with specific vesting schedules[11]. - The Option will vest over four years, with 25% vesting on the first anniversary of January 8, 2026, and the remainder vesting in 36 equal monthly installments[11]. Employment Terms - The Executive's employment is "at will," allowing termination by either party at any time for any reason[3]. - The Company may terminate the Executive's employment without Cause at any time, with specific conditions outlined for termination[18]. - The Executive may terminate employment for Good Reason, which includes material changes in title, salary, or location[19]. Termination and Severance - Upon termination, the Executive will receive any earned but unpaid Base Salary and accrued but unused vacation[25]. - The Executive will be deemed to have resigned from all officer and board member positions upon termination of employment[26]. - If the Executive's employment is terminated without Cause, the Company will pay a Severance Amount equal to 12 months of Base Salary plus a prorated Target Bonus[28]. - In the event of termination within the Change in Control Period, the Executive will receive a lump sum of 18 months of Base Salary plus 1.5 times the Target Bonus for the current year plus a Prorated Bonus[33]. - The Company will pay the Prior Year Bonus if the termination occurs after the end of a calendar year and the annual incentive compensation has been approved but not yet paid[34]. - Health insurance contributions will be made for up to 18 months post-termination, subject to the Executive's copayment and COBRA election[34]. - Time-Based Equity Awards will immediately accelerate and become fully vested upon termination within the Change in Control Period[34]. - Payments under the severance agreement will commence within 60 days after the Date of Termination, with specific provisions for tax implications[35]. - Aggregate Payments may be reduced to avoid excise tax under Section 4999 of the Code, ensuring a higher After Tax Amount for the Executive[37]. - The Company will determine if the Executive is a "specified employee" under Section 409A, which may delay certain payments for six months[41]. Reimbursements and Agreements - All reimbursements for in-kind benefits must be provided within specified time frames and cannot affect benefits in other taxable years[42]. - Payments classified as "non-qualified deferred compensation" will only be made upon the Executive's separation from service as defined by the applicable regulations[43]. - The Executive is required to enter into a Restrictive Covenants Agreement, which includes noncompetition and nonsolicitation provisions, as a condition of employment[46]. - The Company will reimburse the Executive for reasonable out-of-pocket expenses incurred in connection with obligations related to litigation and regulatory cooperation[48]. - The Agreement may be amended to comply with Section 409A of the Code without additional cost to either party[44]. - The Executive's eligibility for equity, cash incentive, and severance compensation is considered sufficient consideration for the Restrictive Covenant Agreement[46]. - The Company and the Executive will enter into an Indemnification Agreement covering acts while serving on the Board[53]. Legal and Governing Provisions - The Agreement is governed by the laws of the Commonwealth of Massachusetts[63]. - The Executive's employment will be governed by a Limited Term Employment Agreement until the Effective Date[65]. - The Agreement shall survive the termination of the Executive's employment to effectuate its terms[58]. - The Executive waives the right to a jury trial in any proceeding related to this Agreement[52]. - The Agreement constitutes the entire agreement between the parties and supersedes all prior agreements[54].

Core Viewpoint - Tango Therapeutics announces the retirement of founding CEO Dr. Barbara Weber, who will transition to Executive Chair, while Dr. Malte Peters is appointed as President and CEO, effective immediately [1][2][3] Leadership Transition - Dr. Barbara Weber will support the senior management team and work with Dr. Peters to ensure a smooth transition and continued clinical execution throughout 2026 [2] - Alexis Borisy will move from Board Chair to Lead Independent Director [2] Achievements and Future Direction - Dr. Weber expressed pride in the company's accomplishments over the past eight years, particularly in advancing vopimetostat into its first registrational trial [3] - Dr. Peters brings extensive experience in clinical development and leadership, having previously served as Chief Research and Development Officer at MorphoSys AG and held key positions at Novartis [3] Clinical Milestones - The company has renewed its guidance on anticipated clinical milestones for 2026, including combination trials with vopimetostat and daraxonrasib, as well as vopimetostat and zoldonrasib, with initial safety and efficacy data expected in 2026 [4] - Upcoming pivotal studies include vopimetostat monotherapy for second-line pancreatic cancer and TNG456 monotherapy phase 1/2 trial [6]

Core Insights - Tango Therapeutics, Inc. has appointed Mr. Sung Lee to its Board of Directors, bringing over 20 years of finance leadership experience in the biopharmaceutical and technology sectors [1][2] Company Overview - Tango Therapeutics is a clinical-stage biotechnology company focused on developing precision cancer medicines [1] - The company is advancing its lead program, vopimetostat, into registrational studies [2] Leadership Appointment - Mr. Sung Lee's experience includes serving as Executive Vice President and Chief Financial Officer at Cytokinetics since May 2024, and prior roles at Vir Biotechnology, MorphoSys, and Sangamo Therapeutics [2] - He has a strong background in corporate strategy, investor relations, and finance, which will support Tango's late-stage clinical development activities [2] Educational Background - Mr. Lee holds a bachelor's degree in economics from the University of California, Irvine, and a Master of Business Taxation from the University of Southern California [2]